Research is ongoing to find new, safe, effective treatments for COVID-19.

Available treatments include:

  • Remdesivir (Veklury), an antiviral medication that can be administered intravenously (IV) to patients whose symptoms are severe enough to require hospitalization. 

  • Monoclonal antibody (mAb) infusions - these are laboratory-made antibodies given intravenously (IV) to help fight Covid-19 infection and reduce risk of severe disease and hospitalization. NOTE: the only mAb that is effective against Omicron variant is Sotrovimab (Xevudy, from GSK). Infusions are approved for:

    • Treatment of patients who have a positive COVID-19 test within the past 10 days and have not yet been admitted to the hospital and are 12 years of age or older (and at least 40 kg) and are at high risk for developing severe COVID-19 due to one of the following risk factors:

      • age 65 or older​

      • Overweight (body mass index over 25)

      • Pregnancy

      • Chronic kidney disease

      • Diabetes (Type 1 and Type 2)

      • Weakened immune system or are currently receiving immunosuppressive treatment

      • Cardiovascular disease/hypertension

      • Chronic lung disease

      • Sickle cell disease

      • Neurodevelopmental disorders

      • Medical-related technological dependence

    • Post-exposure prophylaxis (prevention) with monoclonal antibody infusions for COVID-19 in anyone who:

      • has had close exposure to COVID-19 and

      • is 12 years of age or older (and weighs at least 40 kg), and 

      • is at high risk for progression to severe COVID-19 due to one of the above risk factors and 

      • is not fully vaccinated, or is ​vaccinated but immunocompromised 
    • Pre-exposure prophylaxis (prevention) for people at very high risk due to compromised immune system  - only 1 long-acting monoclonal antibody combination (Evusheld) has been approved for this use ​

  • Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use, available by prescription only) - received Emergency Use Authorization from FDA on 12/22/21 for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients who meet all of the following criteria:

    • adults and children age 12+

    • weight of at least 40 kilograms or 88 pounds

    • tested positive for COVID-19

    • symptoms started no more than 5 days ago

    • are at high risk for progression to severe COVID-19, including hospitalization or death

  • Other medications and treatment protocols for hospitalized patients depend on the severity of illness, underlying medical conditions, and comorbidities at the time of hospitalization.

  • Multiple new treatments are being developed and evaluated. 

 

While there has been much press coverage of medications such as Plaquenil (hydroxychloroquine) and ivermectin, these are NOT recommended at this time for treatment or prophylaxis against COVID-19.

updated 2/2/22